Outlook Therapeutics, Inc.
OTLKOutlook Therapeutics, Inc. in brief
Outlook Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Iselin, New Jersey, USA. Its market value was $119 M on 30 October 2026, which makes it the 18,103rd largest listed company in the world and the 3,429th largest in the USA on this site. In the year to September 2025 it had sales of $1 M and a net loss of $62 M. Robert Charles Jahr is its chief executive. Its largest business segments by sales in 2025 were Development and commercialization of ONS-5010/LYTENAVA (100%). Its shares trade under the symbol OTLK (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a late clinical stage biopharmaceutical company. The company total assets are 19.7 million USD as on 2020. The headquarters is in USA.
Outlook Therapeutics, Inc. timeline
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2016
- 🔔Initial public offering as Oncobiologics, Inc.Final prospectus filed with the SEC on 13 May 2016; shares registered for exchange trading on 11 May 2016.
- 2018
- ✎Renamed Outlook Therapeutics, Inc.Formerly Oncobiologics, Inc..
- 2019
- 💰Record revenue of $8 millionFY2019, the highest of the 3 years on record.
Events of Outlook Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,490 (Jan 2022) · #3,676 (Dec 2022) · #2,845 (Jul 2023) · #3,633 (Jan 2024) · #2,225 (Mar 2026) · #3,267 (Aug 2026) · #3,327 (Oct 2026) · #3,432 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 84.6×
- Price / book
- —
- Free cash flow yield
- -27.4%
- Net margin
- -4427.0%
- Operating margin
- -4756.0%
- Return on equity
- —
- Liabilities / assets
- 273.3%
- Net debt
- $1.1B
- Revenue growth
- -82.7%
- R&D / revenue
- 1927.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $1M | — | $-67M | $-62M | -4427.0% |
| Sep 2024 | — | — | $-72M | $-75M | — |
| Sep 2023 | — | — | $-53M | $-59M | — |
| Sep 2022 | — | — | $-63M | $-66M | — |
| Sep 2021 | — | — | $-52M | $-53M | — |
| Sep 2020 | — | — | $-37M | $-35M | — |
| Sep 2019 | $8M | +163.8% | $-36M | $-35M | -423.6% |
| Sep 2018 | $3M | — | $-30M | $-30M | -973.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Sep 2025 | $-52M | — | — | $-1.79 | — |
| Sep 2024 | $-69M | — | — | $-4.06 | — |
| Sep 2023 | $-43M | — | — | $-4.72 | — |
| Sep 2022 | $-57M | — | — | $-0.31 | — |
| Sep 2021 | $-54M | — | — | $-0.35 | — |
| Sep 2020 | $-32M | — | — | $-0.67 | — |
| Sep 2019 | $-32M | $0M | $-33M | $-1.98 | — |
| Sep 2018 | $-33M | $3M | $-36M | $-1.22 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-20M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Sep 30, 20268-KCurrent reportListing notice
- Sep 18, 20268-KCurrent reportOther events
- Aug 27, 20268-KCurrent reportDirectors or officers changed
- Aug 18, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportOther events
- Aug 14, 20268-KCurrent reportResults of operations
- Aug 12, 20268-KCurrent reportResults of operations · Other events
- Jul 24, 20268-KCurrent reportOther events
- Jul 24, 20268-KCurrent reportDirectors or officers changed
- Jul 16, 20268-KCurrent reportBylaws amended · Shareholder vote
- Jun 26, 20268-KCurrent reportListing notice
- Jun 16, 20268-KCurrent reportOther events
Official filings of Outlook Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-67 M
- Net income
- $-62 M
For year ending September-2025 · source: SEC filing
Balance sheet
- Total assets
- $19 M
- Total liabilities
- $51 M
- Total equity
- $-32 M
As of September-2025
Top 82 institutional investors in Outlook Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Empery Asset Management, LP | 21,247,856 | New | 8.73% | $12 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 8,976,833 | +4,599,961 (+105.10%) | 3.69% | $5 M | Nov 13, 2026 |
| 3 | Marshall Wace, LLP | 8,023,703 | +6,036,125 (+303.69%) | 3.30% | $5 M | Nov 13, 2026 |
| 4 | Ameriprise Financial Inc | 5,050,505 | New | 2.07% | $3 M | Nov 16, 2026 |
| 5 | UBS Group AG | 3,343,234 | +3,191,019 (+2096.39%) | 1.37% | $2 M | Nov 10, 2026 |
| 6 | Perceptive Advisors LLC | 3,139,216 | 0 (0.00%) | 1.29% | $2 M | Nov 16, 2026 |
| 7 | Geode Capital Management, LLC | 1,716,408 | +470,540 (+37.77%) | 0.70% | $1 M | Nov 6, 2026 |
| 8 | BlackRock, Inc. | 1,667,775 | -804 (-0.05%) | 0.69% | $1 M | Nov 13, 2026 |
| 9 | Two Sigma Investments, LP | 1,634,105 | New | 0.67% | $1 M | Nov 16, 2026 |
| 10 | Susquehanna International Group, LLP | 1,422,923 | +454,733 (+46.97%) | 0.58% | $1 M | Nov 16, 2026 |
| 11 | Renaissance Technologies LLC | 1,120,688 | New | 0.46% | $1 M | Nov 12, 2026 |
| 12 | Vanguard Fiduciary Trust Co | 1,067,919 | +406,255 (+61.40%) | 0.44% | $1 M | Nov 13, 2026 |
| 13 | Gilpin Wealth Management, LLC | 625,000 | +70,000 (+12.61%) | 0.26% | $0 M | Oct 9, 2026 |
| 14 | State Street Corp | 569,702 | +29,900 (+5.54%) | 0.23% | $0 M | Nov 12, 2026 |
| 15 | Northern Trust Corp | 409,661 | +172,100 (+72.44%) | 0.17% | $0 M | Nov 16, 2026 |
| 16 | Hudson Bay Capital Management LP | 383,687 | New | 0.16% | $0 M | Nov 13, 2026 |
| 17 | Gsa Capital Partners LLP | 368,909 | New | 0.15% | $0 M | Nov 16, 2026 |
| 18 | Raymond James Financial Inc | 332,051 | 0 (0.00%) | 0.14% | $0 M | Nov 12, 2026 |
| 19 | Citigroup Inc | 221,657 | +220,892 (+28874.77%) | 0.09% | $0 M | Nov 4, 2026 |
| 20 | Cantor Fitzgerald, L. P. | 220,513 | -229,487 (-51.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 21 | Persistent Asset Partners Ltd | 198,655 | New | 0.08% | $0 M | Nov 13, 2026 |
| 22 | WINTON GROUP Ltd | 188,282 | New | 0.08% | $0 M | Nov 12, 2026 |
| 23 | Jane Street Group, LLC | 158,648 | -1,266,622 (-88.87%) | 0.07% | $0 M | Nov 12, 2026 |
| 24 | Citadel Advisors LLC | 138,818 | New | 0.06% | $0 M | Nov 16, 2026 |
| 25 | Tudor Investment Corp Et Al | 132,217 | New | 0.05% | $0 M | Nov 16, 2026 |
Show all 82: investors 26 to 82
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Royal Fund Management, LLC | 111,415 | +64,215 (+136.05%) | 0.05% | $0 M | Oct 22, 2026 |
| 27 | Jefferies Financial Group Inc. | 62,500 | 0 (0.00%) | 0.03% | $0 M | Nov 5, 2026 |
| 28 | NewEdge Advisors, LLC | 60,669 | +43,947 (+262.81%) | 0.02% | $0 M | Nov 13, 2026 |
| 29 | LPL Financial LLC | 54,283 | -130,659 (-70.65%) | 0.02% | $0 M | Nov 6, 2026 |
| 30 | Christensen, King & Associates Investment Services, Inc. | 54,066 | +25,739 (+90.86%) | 0.02% | $0 M | Oct 22, 2026 |
| 31 | Corient Private Wealth LP | 50,300 | New | 0.02% | $0 M | Nov 16, 2026 |
| 32 | MAI Capital Management | 50,000 | New | 0.02% | $0 M | Nov 12, 2026 |
| 33 | Flower City Capital | 50,000 | +30,000 (+150.00%) | 0.02% | $0 M | Oct 15, 2026 |
| 34 | Morgan Stanley | 45,069 | +28,113 (+165.80%) | 0.02% | $0 M | Nov 13, 2026 |
| 35 | Vanguard Global Advisers, LLC | 41,137 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 36 | Harbour Investments, Inc. | 40,812 | +28,508 (+231.70%) | 0.02% | $0 M | Nov 9, 2026 |
| 37 | Group One Trading LLC | 36,349 | -210,079 (-85.25%) | 0.01% | $0 M | Nov 10, 2026 |
| 38 | Warberg Asset Management LLC | 35,177 | New | 0.01% | $0 M | Nov 2, 2026 |
| 39 | Diadema Partners LP | 35,000 | New | 0.01% | $0 M | Nov 16, 2026 |
| 40 | Cerity Partners LLC | 34,691 | New | 0.01% | $0 M | Nov 13, 2026 |
| 41 | Scotia Capital Inc. | 26,300 | -20,000 (-43.20%) | 0.01% | $0 M | Nov 10, 2026 |
| 42 | Jpmorgan Chase & Co | 26,215 | +18,245 (+228.92%) | 0.01% | $0 M | Nov 12, 2026 |
| 43 | PNC Financial Services Group, Inc. | 25,000 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 44 | Optiver Holding B.V. | 21,332 | New | 0.01% | $0 M | Nov 16, 2026 |
| 45 | Clearwater Capital Advisors, LLC | 20,000 | New | 0.01% | $0 M | Nov 6, 2026 |
| 46 | Engineers Gate Manager LP | 19,953 | New | 0.01% | $0 M | Nov 16, 2026 |
| 47 | Bank of New York Mellon Corp | 18,664 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 48 | Cora Capital Advisors LLC | 18,000 | New | 0.01% | $0 M | Nov 2, 2026 |
| 49 | FSA Advisors, Inc. | 16,898 | New | 0.01% | $0 M | Nov 10, 2026 |
| 50 | Oppenheimer & Co Inc | 16,500 | +2,500 (+17.86%) | 0.01% | $0 M | Oct 26, 2026 |
| 51 | HighTower Advisors, LLC | 16,425 | New | 0.01% | $0 M | Nov 10, 2026 |
| 52 | Vanguard Personalized Indexing Management, LLC | 15,716 | -8,403 (-34.84%) | 0.01% | $0 M | Nov 16, 2026 |
| 53 | Orrstown Financial Services Inc | 15,000 | 0 (0.00%) | 0.01% | $0 M | Oct 14, 2026 |
| 54 | Creative Planning | 13,693 | New | 0.01% | $0 M | Nov 2, 2026 |
| 55 | Goldman Sachs Group Inc | 13,671 | New | 0.01% | $0 M | Nov 16, 2026 |
| 56 | Simplicity Wealth,LLC | 13,310 | +2,000 (+17.68%) | 0.01% | $0 M | Oct 23, 2026 |
| 57 | Fifth Third Wealth Advisors LLC | 10,000 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 58 | Osaic Holdings, Inc. | 9,063 | -2,403 (-20.96%) | 0.00% | $0 M | Nov 12, 2026 |
| 59 | Jacobi Capital Management LLC | 8,080 | New | 0.00% | $0 M | Nov 5, 2026 |
| 60 | Rockefeller Capital Management L.P. | 8,000 | +1,750 (+28.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 61 | Bullock Wealth Management Group | 7,112 | +3,000 (+72.96%) | 0.00% | $0 M | Oct 9, 2026 |
| 62 | GoalVest Advisory LLC | 3,000 | 0 (0.00%) | 0.00% | $0 M | Oct 2, 2026 |
| 63 | Jones Financial Companies Lllp | 2,500 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 64 | Northwestern Mutual Wealth Management Co | 2,125 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 65 | Deutsche Bank AG\ | 2,000 | -128,700 (-98.47%) | 0.00% | $0 M | Nov 6, 2026 |
| 66 | Global Retirement Partners, LLC | 1,500 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 67 | Fortitude Family Office, LLC | 1,429 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 68 | Wells Fargo & Company/mn | 1,410 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 69 | Nuveen, LLC | 1,152 | New | 0.00% | $0 M | Nov 10, 2026 |
| 70 | Ancora Advisors LLC | 1,100 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 71 | SBI Securities Co., Ltd. | 511 | +289 (+130.18%) | 0.00% | $0 M | Oct 22, 2026 |
| 72 | EverSource Wealth Advisors, LLC | 363 | -333 (-47.84%) | 0.00% | $0 M | Nov 4, 2026 |
| 73 | Royal Bank Of Canada | 241 | +85 (+54.49%) | 0.00% | $0 M | Nov 16, 2026 |
| 74 | Armstrong Advisory Group, Inc | 179 | 0 (0.00%) | 0.00% | $0 M | Oct 9, 2026 |
| 75 | BNP Paribas Financial Markets | 177 | -128 (-41.97%) | 0.00% | $0 M | Nov 12, 2026 |
| 76 | Larson Financial Group LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 77 | Prestige Wealth Management Group LLC | 62 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 78 | Barclays PLC | 61 | New | 0.00% | $0 M | Nov 6, 2026 |
| 79 | BFC Planning, Inc. | 61 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 80 | Federation des caisses Desjardins du Quebec | 25 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 81 | Bogart Wealth, LLC | 5 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 82 | FMR LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Outlook Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 3.07 M | $5 M | 2.2% | <0.01% | +226% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.23 M | $2 M | 0.87% | <0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 382,684 | $0 M | 0.27% | <0.01% | +138% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 46,106 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 29,620 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 57,557 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 52,929 | $0 M | 0.04% | <0.01% | +31% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 7,574 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 603 | $0 M | <0.01% | <0.01% | +91% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Outlook Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Lawrence A. KenyonChief Financial Officer, Director | Buy | +101,010 | — | — | 106,956 | Form 4 |
| filed | Robert Charles JahrChief Executive Officer, Director | Buy | +151,515 | — | — | 151,515 | Form 4 |
| filed | Ghiath M. SukhtianDirector, 10% owner | Buyindirect | +2.53 M | $0.990 | $2.5 M | 24.62 M | Form 4 |
| filed | Faisal Ghiath SukhtianDirector | Buy | +95,398 | $1.050 | $100 K | 220,972 | Form 4 |
| filed | Yezan Munther HaddadinDirector | Buy | +29,000 | $0.830 | $24 K | 66,167 | Form 4 |
| filed | GMS Ventures & InvestmentsDirector, 10% owner | Buyindirect | +8.54 M | $0.590 | $5.0 M | 22.09 M | Form 4 |
| filed | Faisal Ghiath SukhtianDirector | Buy | +122,174 | $0.410 | $50 K | 125,574 | Form 4 |
| filed | Kurt J. HilzingerDirector | Buy | +400,000 | $0.440 | $176 K | 423,655 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Outlook Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split ; 1-for-8 reverse split
Trading halts
- 2026-07-24 19:00 UTC, code LUDP, resumed 19:05 UTC
- 2026-07-24 17:34 UTC, code T3, resumed 19:00 UTC
- 2025-12-31 21:10 UTC, code T3, resumed 21:35 UTC
- 2024-11-27 16:31 UTC, code LUDP, resumed 16:36 UTC
- 2024-11-27 15:56 UTC, code LUDP, resumed 16:01 UTC
Fails to deliver
- : 636,933 shares at $0.49
- : 192,078 shares at $0.54
- : 61,859 shares at $0.53
- : 12,252 shares at $0.56
- : 29,959 shares at $0.56
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Outlook Therapeutics, Inc. scorecard#
Passes 0 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median84.6×Price to sales 84.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-27.4%Free cash flow is -27.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.79 vs -4.06Diluted EPS -1.79 in fiscal 2025 against -4.06 the year before (report's currency).
- ✗Net income higher than five years earlier-$62 M-$62 M in fiscal 2025 against -$35 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$62 MNet income -$62 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.38 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-57.90Z-score -57.90 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year87.6%Diluted shares up 87.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Outlook Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Sep 30, 2025 | FY 2024to Sep 30, 2024 | FY 2023to Sep 30, 2023 | FY 2022to Sep 30, 2022 | FY 2021to Sep 30, 2021 | FY 2020to Sep 30, 2020 | FY 2019to Sep 30, 2019 | FY 2018to Sep 30, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 1.4—100% | — | — | — | — | — | 8.1+164%100% | 3.1−19.0%100% | 3.8+27.9%100% | 3.0—100% | |
| Cost of revenue | 1.4—96.0% | — | — | — | — | — | — | — | — | — | |
| Gross profit | 0.1—4.0% | — | — | — | — | — | — | — | — | — | |
| Research and development | 27−34.9%1923% | 42+57.9%— | 26−37.5%— | 42+8.7%— | 39+47.9%— | 26+10.7%— | 24+28.6%292% | 19−22.3%599% | 24−27.3%625% | 33r33—1100% | |
| Selling, general and administrative | 40+33.4%2825% | 30—— | — | — | — | — | — | — | — | — | |
| General and administrative | — | 30+12.2%— | 27+28.6%— | 21+62.4%— | 13+28.1%— | 10.0+6.4%— | 9.4−34.1%115% | 14−10.4%461% | 16−26.3%417% | 22r22—724% | |
| Operating expenses | — | — | — | — | 52+40.4%— | 37−17.1%— | 44+35.8%546% | 33−17.5%1060% | 40−26.9%1041% | 54r55—1823% | |
| Operating income | −67—−4744% | −72—— | −53—— | −63—— | −52—— | −37—— | −36—−446% | −30—−960% | −36—−941% | −51r−52—−1723% | |
| Interest and finance income | 0.1−90.1%6.3% | 0.9−6.7%— | 1.0—— | — | — | — | — | — | — | — | |
| Interest expense and finance costs | — | 3.2+24.7%— | 2.5—— | — | — | 1.8−49.3%— | 3.5−10.9%42.6% | 3.9−30.8%126% | 5.6+204%148% | 1.9r1.5—62.2% | |
| Net interest income | −0.3—−20.0% | −3.2—— | −1.6—— | −1.5—— | −0.9—— | −1.8—— | — | — | — | — | |
| Share of profit of associates | −0.1—−10.0% | −0.1—— | −0.0—— | −0.0—— | −0.0—— | — | — | — | — | — | |
| Income before tax | −64—−4526% | −75—— | −59—— | −66—— | −53—— | −39—— | −38—−466% | −34—−1093% | −38—−1006% | −53r−53—−1785% | |
| Income tax | −1.6−55522%−110% | 0.00.0%— | 0.00.0%— | 0.0+40.0%— | 0.0—— | −3.3—— | −3.4—−41.9% | −3.6−827%−118% | 0.5+387%13.2% | 0.1—3.5% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | −53—−1790% | |
| Net income attributable to shareholders | −62—−4416% | −75—— | −59—— | −66—— | −53—— | −35—— | −35—−424% | −30—−975% | −39—−1019% | −53r−53—−1789% | |
| Earnings per share, basic | -1.79—— | -4.06—— | -4.72r-0.24—— | -0.31—— | -0.35—— | -0.67—— | -1.98—— | -1.22—— | -1.67—— | -3.67—— | |
| Earnings per share, diluted | -1.79—— | -4.06—— | -4.72r-0.24—— | -0.31—— | -0.35—— | -0.67—— | -1.98—— | -1.22—— | -1.80—— | -3.67—— | |
| Shares, weighted average (basic) | 35+87.6%— | 19+48.3%— | 13r250−94.1%— | 212+38.9%— | 153+110%— | 73—— | — | 39+64.3%— | 24+39.6%— | 17—— | |
| Shares, weighted average (diluted) | 35+87.6%— | 19+48.3%— | 13r250−94.1%— | 212+38.9%— | 153+110%— | 73+299%— | 18−53.9%— | 39+64.1%— | 24+39.7%— | 17—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.1−45.9%43.5% | 15−36.2%51.8% | 23+34.5%72.4% | 17+20.2%61.0% | 14+15.5%63.5% | 13+56.4%63.5% | 8.0+367%46.8% | 1.7−46.1%7.7% | 3.2+35.4%15.4% | 2.4—9.3% | |
| Receivables | 1.5—8.0% | — | — | — | — | — | — | — | — | — | |
| Inventory | 3.3—18.0% | — | — | — | — | — | — | — | — | — | |
| Other current assets | 4.5−64.2%24.1% | 12+64.6%43.3% | 7.6−25.1%23.5% | 10+44.0%35.5% | 7.0+30.0%30.8% | 5.4+8.5%27.4% | 5.0+215%29.1% | 1.6+120%7.1% | 0.7−78.4%3.5% | 3.3—13.1% | |
| Current assets | 17−36.6%93.6% | 27−11.5%95.1% | 31+12.6%95.9% | 28+28.0%96.5% | 22+19.9%94.3% | 18+32.9%90.9% | 14+309%78.8% | 3.3−15.4%14.8% | 3.9−31.2%18.8% | 5.7—22.4% | |
| Property, plant and equipment | — | — | — | — | 0.2−50.0%0.7% | 0.3−89.7%1.7% | 3.2−82.8%18.5% | 18+14.9%83.0% | 16−13.8%77.6% | 19r17—73.4% | |
| Right-of-use (leased) assets | 0.2−17.9%1.2% | 0.3+949%1.0% | 0.0−62.8%0.1% | 0.1−36.9%0.2% | 0.1−33.3%0.5% | 0.2—0.8% | — | — | — | — | |
| Investments in associates | 0.6−20.3%3.0% | 0.7−12.7%2.4% | 0.8−1.4%2.5% | 0.8−5.7%2.8% | 0.9—3.7% | — | — | — | — | — | |
| Total assets | 19−35.5%100% | 29−10.8%100% | 32+13.2%100% | 29+25.1%100% | 23+15.6%100% | 20+15.2%100% | 17−23.1%100% | 22+7.5%100% | 21−18.4%100% | 25r24—100% | |
| Accounts payable | 10+27.9%54.8% | 8.0+21.2%27.6% | 6.6+88.3%20.4% | 3.5+59.0%12.2% | 2.2−8.3%9.6% | 2.4+5.1%12.1% | 2.3−36.9%13.3% | 3.6−67.0%16.2% | 11+116%52.8% | 5.1—20.0% | |
| Debt due within a year | — | — | — | — | — | — | 1,026r1.0+1543474%5989% | 0.1+26.4%0.3% | 0.1−91.0%0.3% | 0.6—2.3% | |
| Current liabilities | 46+7.7%247% | 43−8.9%148% | 47+137%145% | 20+192%69.2% | 6.8−57.5%29.6% | 16−21.7%80.5% | 20−36.7%118% | 32+11.5%144% | 29+40.6%139% | 20—80.4% | |
| Long-term debt | — | — | — | — | — | — | 50r0.1+50957%293% | 0.1−34.8%0.4% | 0.2−93.2%0.7% | 2.2—8.8% | |
| Lease liabilities (non-current) | 0.2−23.5%1.0% | 0.2—0.9% | — | — | 0.0—0.1% | — | — | — | — | — | |
| Total liabilities | 51−50.2%273% | 102+118%354% | 47+136%145% | 20+8.7%69.4% | 18+7.7%79.8% | 17−39.4%85.7% | 28−35.2%163% | 43−16.3%193% | 51+68.3%248% | 31r29—120% | |
| Retained earnings | −606—−3259% | −543—−1885% | −468—−1449% | −409—−1433% | −343—−1503% | −290—−1468% | −254—−1485% | −216—−971% | −186—−898% | −147r−147—−580% | |
| Shareholders' equity | −32—−173% | −73—−254% | −14−265%−44.7% | 8.7+89.6%30.6% | 4.6+63.0%20.2% | 2.8—14.3% | −16—−94.1% | −26—−115% | −34—−162% | −5.2r−5.2—−20.4% | |
| Total equity | — | — | — | — | — | — | — | — | — | −5.2—−20.5% | |
| Total liabilities and equity | 19−35.5%100% | 29−10.8%100% | 32+13.2%100% | 29+25.1%100% | 23+15.6%100% | 20+15.2%100% | 17−23.1%100% | 22+7.5%100% | 21−18.4%100% | 25r24—100% | |
| Shares outstanding | 54+125%— | 24+83.7%— | 13r260−94.3%— | 227+28.8%— | 176+38.7%— | 127+345%— | 29+217%— | 9.0r72−63.8%— | 25+9.3%— | 23—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1+2.8%8.3% | 0.1+158%— | 0.0−78.4%— | 0.2−21.9%— | 0.3+19.5%— | 0.2−93.5%— | 3.4+10.1%41.3% | 3.1r3.1+13.5%98.9% | 2.7+12.4%70.6% | 2.4—80.4% | |
| Share-based compensation | 8.9+65.2%629% | 5.4−2.9%— | 5.5−28.1%— | 7.7+57.8%— | 4.9+74.1%— | 2.8+114%— | 1.3−33.9%16.1% | 2.0−76.8%64.3% | 8.6−31.2%225% | 12—418% | |
| Cash from operating activities | −52—−3667% | −69—— | −43—— | −57—— | −54—— | −32—— | −32—−396% | −33—−1070% | −16—−407% | −45—−1526% | |
| Capital expenditure | — | — | — | — | — | — | −0.4—−5.4% | −2.8—−90.1% | −0.3—−7.7% | −1.1—−36.9% | |
| Cash from investing activities | — | — | — | — | — | −0.9—— | −0.4—−5.4% | −2.8—−90.1% | −0.3—−7.7% | −1.1—−36.9% | |
| Debt issued | 33—2342% | — | 30+200%— | 100.0%— | 10+1006%— | 0.9—— | — | — | — | 0.2—6.7% | |
| Debt repaid | −36—−2557% | — | −10—— | −12—— | −0.1—— | −0.0—— | −6.4—−78.8% | −0.1—−4.1% | −2.7—−70.3% | −1.1—−35.5% | |
| Shares issued | 25−57.9%1797% | 60+101%— | 30−51.8%— | 62+34.6%— | 46+30.7%— | 35−22.9%— | 46+213%564% | 15+814%476% | 1.6−90.0%42.2% | 16—542% | |
| Cash from financing activities | 45−25.4%3182% | 60+23.2%— | 49−17.8%— | 60+6.0%— | 56+51.0%— | 37−4.7%— | 39+13.6%479% | 34+107%1113% | 17−58.3%436% | 40—1338% | |
| Change in cash | −6.8—−484% | −8.5−241%— | 6.0+105%— | 2.9+50.4%— | 1.9−57.1%— | 4.5−28.2%— | 6.3—77.3% | −1.5−276%−47.5% | 0.8—21.9% | −6.7—−226% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q3 FY2026to Jun 30, 2026 | Q2 FY2026to Mar 31, 2026 | Q1 FY2026to Dec 31, 2025 | Q4 FY2025to Sep 30, 2025 | Q3 FY2025to Jun 30, 2025 | Q2 FY2025to Mar 31, 2025 | Q1 FY2025to Dec 31, 2024 | Q4 FY2024to Sep 30, 2024 | Q3 FY2024to Jun 30, 2024 | Q2 FY2024to Mar 31, 2024 | Q1 FY2024to Dec 31, 2023 | Q4 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | 1.5—100% | — | — | — | — | — | — | — | |
| Cost of revenue | 1.1—— | 0.0−96.1%— | 0.1—— | 0.0—— | 0.9*—— | 0.4—29.2% | — | — | — | — | — | — | — | |
| Gross profit | −2.3—— | −0.0−101%— | −0.0—— | −1.2—— | −1.0*—— | 1.1—70.8% | — | — | — | — | — | — | — | |
| Research and development | 17−48.5%— | 3.3−54.4%— | 4.5+2.1%— | 3.6−62.4%— | 6.0*−52.3%— | 7.1−36.3%474% | 4.4−67.4%— | 9.7+113%— | 13*+153%— | 11—— | 14—— | 4.5—— | 4.9*—— | |
| Selling, general and administrative | 36−9.9%— | 7.6−22.0%— | 9.5+19.0%— | 8.6−27.9%— | 10*−0.3%— | 9.7+15.8%643% | 8.0—— | 12—— | 10*—— | 8.4—— | — | — | — | |
| General and administrative | — | — | — | — | — | — | 8.0+47.0%— | 12+106%— | 10*+37.8%— | 8.4—— | 5.4—— | 5.8—— | 7.5*—— | |
| Operating expenses | — | — | — | — | — | — | — | — | — | 20—— | 19—— | — | — | |
| Operating income | −56—— | −11—— | −14—— | −13—— | −17*—— | −16—−1046% | −12—— | −22—— | −23*—— | −20—— | −19—— | −10—— | −12*—— | |
| Interest and finance income | — | — | — | — | — | — | — | — | 0.2*−21.6%— | 0.4—— | — | — | 0.3*—— | |
| Net interest income | −0.3—— | 0.0—— | 0.0—— | 0−100%— | −0.3*—— | −0.0−112%−3.3% | −0.0—— | 0.0−74.1%— | −0.7*−318%— | 0.4—— | −3.1—— | 0.2—— | 0.3*—— | |
| Share of profit of associates | −0.2—— | −0.0—— | −0.0—— | −0.0—— | −0.0*—— | −0.0—−2.1% | −0.0—— | −0.0−1407%— | −0.0*—— | −0.1—— | −0.0—— | 0.0—— | −0.0*—— | |
| Income before tax | — | −20—— | −4.5—— | — | −15*−361%— | −20−145%−1339% | −46—— | — | 5.7*—— | 44—— | −114—— | — | −13*—— | |
| Income tax | — | — | — | — | −1.6*—— | 0*—0.0% | 0.00.0%— | — | 0*—— | 0*—— | 0.0—— | — | 0*—— | |
| Net income attributable to shareholders | −61—— | −20—— | −4.5—— | −23−233%— | −13*−334%— | −20−145%−1339% | −46—— | 17—— | 5.7*—— | 44—— | −114—— | −11—— | −13*—— | |
| Earnings per share, basic | — | -0.15—— | -0.05—— | -0.38−153%— | — | -0.55−129%— | -1.50—— | 0.72—— | — | 1.91—— | -8.01—— | -0.86r-0.04—— | — | |
| Earnings per share, diluted | — | -0.15—— | -0.05—— | -0.38−153%— | — | -0.55—— | -1.50—— | 0.72—— | — | -0.89—— | -8.01—— | -0.86r-0.04—— | — | |
| Shares, weighted average (basic) | 137+270%— | 137+270%— | 82+165%— | 60+148%— | — | 37+59.1%— | 31+116%— | 24+86.2%— | — | 23—— | 14—— | 13r260—— | — | |
| Shares, weighted average (diluted) | 137+270%— | 137+270%— | 82+165%— | 60+148%— | — | 37+45.1%— | 31+116%— | 24+86.2%— | — | 25—— | 14—— | 13r260—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 11—42.9% | 11+26.3%42.9% | 7.7+2.5%35.4% | 8.7+52.2%47.6% | 8.1−45.9%43.5% | 8.9−72.2%39.8% | 7.6−84.0%39.6% | 5.7−44.9%33.5% | 15−36.2%51.8% | 32—68.0% | 47—80.0% | 10—47.8% | 23—72.4% | |
| Receivables | 1.6—6.3% | 1.6−6.1%6.3% | 2.7—12.4% | 0.1—0.6% | 1.5—8.0% | 1.8—7.8% | — | — | — | — | — | — | — | |
| Inventory | 5.0—19.3% | 5.0+22.2%19.3% | 3.3−7.2%15.3% | 3.5+11.2%19.0% | 3.3—18.0% | 4.1—18.4% | 3.6—18.9% | 3.1—18.3% | — | — | — | — | — | |
| Other current assets | 5.2—20.0% | 5.2−17.1%20.0% | 7.1+6.7%32.4% | 4.9−28.3%27.0% | 4.5−64.2%24.1% | 6.3−53.5%28.2% | 6.6−37.0%34.8% | 6.9−31.7%40.3% | 12+64.6%43.3% | 14—28.9% | 11—17.9% | 10—46.3% | 7.6—23.5% | |
| Current assets | 23—88.5% | 23+9.8%88.5% | 21+17.4%95.5% | 17+9.6%94.1% | 17−36.6%93.6% | 21−53.8%94.2% | 18−69.2%93.4% | 16−23.2%92.1% | 27−11.5%95.1% | 46—96.9% | 58—97.9% | 20—94.0% | 31—95.9% | |
| Right-of-use (leased) assets | 0.2—0.7% | 0.2−22.3%0.7% | 0.2−20.6%0.9% | 0.2−19.2%1.2% | 0.2−17.9%1.2% | 0.2−16.8%1.1% | 0.3+6605%1.3% | 0.3+1657%1.5% | 0.3+949%1.0% | 0.3—0.6% | 0.0—0.0% | 0.0—0.1% | 0.0—0.1% | |
| Investments in associates | 2.5—9.7% | 2.5+326%9.7% | 0.5−24.9%2.1% | 0.5−22.2%2.8% | 0.6−20.3%3.0% | 0.6−16.3%2.6% | 0.6−18.6%3.3% | 0.7−17.1%3.9% | 0.7−12.7%2.4% | 0.7—1.5% | 0.8—1.3% | 0.8—3.7% | 0.8—2.5% | |
| Total assets | 26—100% | 26+16.9%100% | 22+14.8%100% | 18+7.2%100% | 19−35.5%100% | 22−52.5%100% | 19−67.7%100% | 17−21.6%100% | 29−10.8%100% | 47—100% | 59—100% | 22—100% | 32—100% | |
| Accounts payable | 6.8—26.0% | 6.8−33.7%26.0% | 14+75.6%62.3% | 7.3−40.0%40.1% | 10+27.9%54.8% | 10+84.8%45.8% | 7.8+78.0%40.7% | 12+250%71.7% | 8.0+21.2%27.6% | 5.6—11.8% | 4.4—7.4% | 3.5—16.0% | 6.6—20.4% | |
| Current liabilities | 29—110% | 29−8.9%110% | 39+56.6%178% | 49+1.7%269% | 46+7.7%247% | 31−26.0%141% | 25−54.1%130% | 48+4.9%284% | 43−8.9%148% | 43—90.4% | 54—91.6% | 46—212% | 47—145% | |
| Lease liabilities (non-current) | 0.1—0.5% | 0.1−31.4%0.5% | 0.2−28.3%0.7% | 0.2−26.2%0.9% | 0.2−23.5%1.0% | 0.2−21.6%0.9% | 0.2—1.1% | 0.2—1.4% | 0.2—0.9% | 0.3—0.6% | — | — | — | |
| Total liabilities | 37—140% | 37−38.6%140% | 51−1.3%232% | 57−15.6%311% | 51−50.2%273% | 60−54.4%266% | 52−73.3%270% | 67+46.2%396% | 102+118%354% | 131—278% | 193—327% | 46—212% | 47—145% | |
| Retained earnings | −654—−2496% | −654—−2496% | −633—−2892% | −629—−3447% | −606—−3259% | −592—−2646% | −572—−3000% | −526—−3092% | −543—−1885% | −549—−1166% | −593—−1005% | −479—−2209% | −468—−1449% | |
| Shareholders' equity | −10—−39.7% | −10—−39.7% | −29—−132% | −39—−211% | −32—−173% | −37—−166% | −32—−170% | −50—−296% | −73—−254% | −84—−178% | −134—−227% | −24—−112% | −14—−44.7% | |
| Total liabilities and equity | 26—100% | 26+16.9%100% | 22+14.8%100% | 18+7.2%100% | 19−35.5%100% | 22−52.5%100% | 19−67.7%100% | 17−21.6%100% | 29−10.8%100% | 47—100% | 59—100% | 22—100% | 32—100% | |
| Shares outstanding | 187—— | 187+330%— | 105+218%— | 65+159%— | 54+125%— | 43+85.8%— | 33+49.5%— | 25−90.4%— | 24+83.7%— | 23—— | 22—— | 260—— | 13r260—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−10.4%— | 0.0*−53.1%— | 0.0*+4.5%— | 0.0+4.4%— | 0.0*+3.3%— | 0.0*+2.6%2.0% | 0.0*+3.2%— | 0.0+2.1%— | 0.0*+157%— | 0.0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 4.3−49.7%— | 0.8−52.6%— | 0.8−55.5%— | 0.9−76.0%— | 1.8*+29.5%— | 1.7+19.7%111% | 1.7+30.0%— | 3.7+189%— | 1.4*+1.2%— | 1.4—— | 1.3—— | 1.3—— | 1.4*—— | |
| Cash from operating activities | −56—— | −21*—— | −7.8*—— | −15—— | −12*—— | −12*—−791% | −17*—— | −11—— | −17*—— | −20*—— | −19*—— | −13—— | −13*—— | |
| Debt issued | — | — | — | — | 0*—— | 0*—0.0% | — | — | — | — | — | — | 0*—— | |
| Debt repaid | — | — | — | — | −2.3*—— | −0.9*—−60.3% | — | — | — | — | — | — | 0*—— | |
| Shares issued | 55+210%— | 25*+72.6%— | 6.9*+387%— | 15+757%— | 7.6r8.1*—— | 15r14*+239%970% | 1.4*—— | 1.7—— | −0.1*−105%— | 4.3*—— | — | — | 2.4*—— | |
| Cash from financing activities | 61+81.9%— | 27*+101%— | 6.9*−62.6%— | 16+792%— | 12*—— | 13*+207%880% | 18*−67.2%— | 1.7—— | −0.1*−105%— | 4.3*—— | 56*—— | −0.0—— | 2.4*—— | |
| Change in cash | 2.3—— | 3.5*+160%— | −0.9*−150%— | 0.6—— | −0.8*—— | 1.3*—89.3% | 1.9*−95.0%— | −9.2—— | −17*—— | −15*—— | 37*—— | −13—— | −10*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Outlook Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Development and commercialization of ONS-5010/LYTENAVA$1 M100%—
Source: SEC annual report (XBRL data) · as of Sep 30, 2025
Where Outlook Therapeutics, Inc. operates: 7 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇦🇺 Australia | 1 subsidiary | — |
| 🇩🇪 Germany | 1 subsidiary | — |
| 🇮🇪 Ireland | 1 subsidiary | — |
| 🇳🇱 Netherlands | 1 subsidiary | — |
| 🇨🇭 Switzerland | 1 subsidiary | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Outlook Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Directors and officers 4 · Material agreement 2 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement endedResults announced | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 30, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2024 | $5 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Mar 2024 | $60 M | Private placement after listing | $50 to $250 million | 21 | equity, options | SEC |
| Dec 2022 | $1 M | Private placement after listing | Under $2 million | 1 | options | SEC |
| Feb 2021 | $4 M | Private placement after listing | $2 to $10 million | 2 | equity | SEC |
| Jun 2020 | $16 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Feb 2020 | $8 M | Private placement after listing | $2 to $10 million | 7 | equity, options | SEC |
| Sep 2017 | $3 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Dec 2015 | $6 M | No. 3 | $2 to $10 million | 11 | equity | SEC |
| Sep 2015 | $14 M | No. 2 | $10 to $50 million | 4 | equity | SEC |
| Jun 2015 | $31 M | No. 1 | $10 to $50 million | 7 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
FDA drug approvals: Outlook Therapeutics, Inc.#
1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2026.
| Approved | Drug | Kind |
|---|---|---|
| 2026-07-24 | Lytenavanew moleculeBevacizumab-Vikg · BLA761320 | Biologic (BLA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (OUTLOOK THERAPEUTICS, INC.), so they follow acquisitions
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | 5 | 5 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 5 people (23% of workforce) | Restructuring planSEC 8-K | “On December 13, 2024, the Company reduced its workforce by 5 people, or approximately 23% of the Company’s existing headcount.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Outlook Therapeutics, Inc. compares in Biotechnology
- Market cap$119 M · higher than 38% of 726
- Revenue$1 M · higher than 28% of 647
- Price / sales84.6× · lower than 12% of 339
- FCF yield-27.4% · higher than 35% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Outlook Therapeutics, Inc.🇺🇸 | $119 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending September-2025
- Balance sheet:
- As of September-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Outlook Therapeutics, Inc.? Verify and update this profile — free
Show Outlook Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.